Fate Therapeutics

Quarterly Financials

Values in thousands2025-09-302025-06-302025-03-312024-12-31
Revenue
$1,741
$1,907
$1,629
$1,860
Gross Profit
1,741
1,907
1,629
1,860
EBITDA
-29,023
-30,792
-37,947
-42,198
EBIT
-32,250
-34,070
-41,280
-47,011
Net Income
-32,250
-34,070
-37,621
-52,153
Net Change In Cash
1,741
1,907
1,629
1,860
Free Cash Flow
-26,577
-25,949
-35,005
-27,897
Cash
40,622
41,249
44,920
36,056
Basic Shares
118,998
118,528
118,375
117,794

Annual Financials

Values in thousands2024-12-312023-12-312022-12-312021-12-31
Revenue
$13,631
$63,533
$96,300
$55,846
Gross Profit
13,631
-93,654
96,300
49,996
EBITDA
-176,577
-172,229
-294,628
-211,144
EBIT
-195,539
-190,511
-308,386
-216,994
Net Income
-186,262
-160,928
-255,056
-212,151
Net Change In Cash
13,631
63,533
96,300
55,846
Cost of Revenue
-33,764
Free Cash Flow
-123,604
-138,416
-283,774
-213,574
Cash
36,056
41,870
61,333
133,583
Basic Shares
113,685
98,411
96,826
94,747

Earnings Calls

QuarterEPS
2025-12-31
$0
2025-09-30
-$0.27
2025-06-30
-$0.29
2025-03-31
-$0.32